What Is Rod and Cone Dystrophy?
Rod and cone dystrophy (also called cone-rod dystrophy or CRD) is a group of degenerative retinal conditions characterised by the progressive deterioration of both cone photoreceptors (responsible for central and colour vision) and rod photoreceptors (responsible for night and peripheral vision). Unlike Retinitis Pigmentosa — where rod degeneration typically precedes cone degeneration — in cone-rod dystrophy, cones are often primarily or simultaneously affected alongside rods. The condition is caused by mutations in a number of genes, with ABCA4, RPGR, GUCY2D, and CNGB3 among those most commonly implicated. Rod and cone dystrophy affects approximately 1 in 30,000–40,000 people and typically presents in the first or second decade of life.
Common Symptoms
Because both rod and cone photoreceptors are affected, rod-cone dystrophy causes a wide spectrum of visual impairment. Common symptoms include: progressive central vision loss — affecting reading, face recognition, and detailed tasks; difficulty seeing in low light or darkness (nyctalopia); progressive loss of peripheral (side) vision leading to tunnel vision; light sensitivity (photophobia) — often pronounced because cone function is compromised; reduced or abnormal colour vision; reduced visual acuity that worsens progressively over time; and photopsia (seeing flashes of light). The condition usually progresses over years to decades, with significant variability between individuals even within the same genetic subtype.
Research & Treatment Development
Research in rod and cone dystrophy is closely linked with broader degenerative retinal disease research and is advancing rapidly. Active areas include: gene-focused therapies targeting the specific mutations responsible for different forms of rod-cone dystrophy — multiple Phase I/II trials are ongoing; advanced medical innovation approaches exploring retinal cell regeneration and photoreceptor replacement; assistive visual technology including high-contrast magnification, dark-adaptation aids, and screen-reading software; precision diagnostic testing using full-field and pattern ERG, OCT, dark adaptometry, and colour vision assessment; retinal prostheses and optogenetic approaches as potential future therapies; and vision preservation approaches using neuroprotective compounds. Our team stays current with the latest published research to inform our treatment protocols.
Our Approach at Med Cure Centre
Med Cure Centre provides specialist diagnosis, assessment, and personalised treatment protocols for patients with rod and cone dystrophy. Dr. Pallavee R. Goswami (Consultant Ophthalmologist, 26 Years Experience) leads our degenerative retinal disease programme and has extensive experience with the full spectrum of photoreceptor dystrophies. We conduct comprehensive diagnostic assessment including genetic testing, electroretinography, and detailed visual function mapping. Treatment protocols are personalised based on genetic subtype, disease stage, and individual visual needs. We treat patients from childhood through adulthood and support international patients with online consultation and remote follow-up.
📄 Scientific References
- National Institutes of Health (NIH) — National Library of Medicine. PubMed database. pubmed.ncbi.nlm.nih.gov
- World Health Organization (WHO) — Neurological Disorders & Eye Health Resources. who.int
- American Academy of Ophthalmology / Neurology — Clinical guidelines and disease statistics. aao.org